Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mind-Controlled robot arm therapy could restore movement after stroke

NCT ID NCT07553416

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a new type of rehabilitation robot that uses brain signals and mirror therapy to help stroke patients with arm weakness. The robot is non-invasive and designed to encourage the brain to re-learn movement. Researchers will enroll 40 adults aged 30 to 80 who had a stroke 1 to 6 months ago and have trouble moving one arm. The goal is to see if this approach improves arm function and helps the brain adapt.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 30 to 80 years 2. Patients with unilateral upper limb motor dysfunction caused by primary ischemic/hemorrhagic stroke within 1 to 6 months prior to enrollment 3. Cerebral magnetic resonance diffusion-weighted imaging (DWI) at the time of onset indicating that the stroke lesion is limited to the unilateral basal ganglia region 4. Modified Rankin Scale (mRS) score of 0 to 2 before stroke onset 5. Fugl-Meyer Motor Function Assessment of Upper Extremities (FMA-UE) score of 10 to 42 6. Montreal Cognitive Assessment (MoCA) score \> 18 7. Fugl-Meyer Balance Assessment score \> 6 8. Normal binocular visual acuity or corrected visual acuity 9. Normal hearing and intact verbal comprehension ability 10. Provided written informed consent Exclusion Criteria: 1. Patients with other severe cardiovascular and cerebrovascular diseases and unstable vital signs 2. Patients with motor dysfunction caused by other etiologies, such as amyotrophic lateral sclerosis, myasthenia gravis, muscular dystrophy, hypokalemic periodic paralysis, spondylitis, arthritis, osteomyelitis, etc. 3. Patients with severe diseases of the lungs, liver, kidneys and other vital organs 4. Patients with limb movement impairment caused by diseases such as fractures and arthritis 5. Modified Ashworth Scale (MAS) score \> 3 6. Patients unable to understand and cooperate with limb rehabilitation training due to factors such as severe aphasia 7. Presence of severe visual field defects or visual impairments (e.g., hemianopsia, hemispatial neglect, etc. 8. History of previous stroke 9. A history of severe motor injury and/or surgical intervention of the affected upper limb, such as muscle tear, tendon rupture, rhabdomyolysis 10. Life expectancy of less than 1 year due to the underlying disease 11. Undergoing major surgery within the past 30 days or planning to undergo major surgery within the next 90 days 12. Pregnant or lactating women 13. History of drug or alcohol abuse, head trauma or central nervous system infection; current use of cognition-impairing medications such as psychoactive or sedative drugs 14. With definite psychiatric and psychological disorders, such as depression, anxiety disorder, obsessive-compulsive disorder, schizophrenia, autism, chronic sleep disorder, consciousness disorder, etc. 15. Having implanted electronic devices in the body that interfere with magnetic resonance imaging (MRI), such as cochlear implants, cardiac pacemakers/defibrillators, drug delivery pumps 16. Poor compliance of the subject, their family members and caregivers, or inability to complete at least 12 months of follow-up as required by the study 17. Having been enrolled in other clinical studies that conflict with this study 18. Judged by the Indication Evaluation Committee as ineligible for or not falling within the scope of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain-computer interfaces are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.